Brought to you by 
Pfizer to build its immuno-oncology pipeline through tie-up with Merck KGAA; Agreement terminated
27 Mar 2023
Executive Summary
Merck KGAA has enlisted the help of Pfizer Inc. to jointly develop and commercialize its MSB0010718C anti-programmed cell death ligand 1 (PD-L1) antibody currently in clinical trials for various cancers.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer to build its immuno-oncology pipeline through tie-up with Merck KGAA; Agreement terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice